mosunetuzumab
roche
['fil,veral,12', 'mosunetuzumab', 'hodgkin', 'ionis ']
congress | #ash22 presents updated results from the phase ii study of mosunetuzumab in patients with r/r #fl. after a median follow-up of 27 months, durable responses continued to be observed with a safety profile in line with previous reports. 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm